Trials / Completed
CompletedNCT01232452
A Study in Non-Small Cell Lung Cancer
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced nonsquamous non-small cell lung carcinoma (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemetrexed | Administered intravenously (IV) |
| DRUG | Cisplatin | Administered IV |
| DRUG | Cixutumumab | Administered IV |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2013-01-01
- Completion
- 2016-06-01
- First posted
- 2010-11-02
- Last updated
- 2019-09-20
- Results posted
- 2018-06-12
Locations
44 sites across 12 countries: United States, Argentina, Belgium, Brazil, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01232452. Inclusion in this directory is not an endorsement.